During the past decade, A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia" are "Multiple Myeloma" (3 trials), "Diffuse Large B-cell Lymphoma" (1 trials), "Lymphoma, Mucosa-Associated Lymphoid Tissue" (1 trials), "Non-Hodgkin Lymphoma" (1 trials) and "Primary Mediastinal B-cell Lymphoma" (1 trials). Many other conditions were trialed in "A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia" in a lesser frequency.

Most popular intervention types in "A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia" are "Drug" (6 trials), "Radiation" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Thalidomide" (2 trials), "3D-Conformal Radiotherapy (3D-CRT)" (1 trials), "BORTEZOMIB" (1 trials), "Carmustine" (1 trials) and "Cytarabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia" are 7 trials for "All" genders.

Currently, there are NaN active trials in "A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".